Prolor touts Ph2 results on growth hormone; Antares racks up promising data on auto injector;

@FierceBiotech: Celgene tackles anemia in $242M development pact with Acceleron. Piece | Follow @FierceBiotech

@JohnCFierce: Bloomberg covers the provenge disaster. Docs confused about coverage? Really? I'm not buying it. | Follow @JohnCFierce

@MaureenFierce: FDA's Woodcock on biosimilars: No "one size fits all" approach. | Follow @MaureenFierce

> Prolor Biotech says that its Phase II study of an injectable human growth hormone hit its endpoints. Its once-weekly dosing is designed to replace seven daily injections. Story

> Antares Pharma says that it racked up positive results for a study of Vibex, an auto injector product designed to give a rapid subcutaneous injection of methotrexate for RA. Release

> Santarus and the Pharming Group announced that the FDA has accepted their Phase III trial design for rhucin, which is being studied for HAE. Release

Pharma News

@FiercePharma: Dendreon cites CMS review for sales trouble, but The Street's take is more plausible: Cash-flow-conscious oncologists. | Follow @FiercePharma

> Europe blesses Pradaxa for stroke prevention. More

> Merck cuts put pharma on top of layoffs list. Piece

> Novo expects slowdown in modern insulins. Story

> Multitalented Botox could get $500M off bladder indication. News

> Surprise Provenge shortfall triggers Dendreon layoffs. Report

> Pfizer eyes OTC Lipitor, but will FDA approve? Article

Manufacturing News

> Musty odor exudes from J&J board report exonerating execs. More

> Pharma slices cargo theft in h1 2011. Report

> FDA foreign force multiplier demo'd in API inspections. Article

> Catalent catches the cold chain wave. News

> Developed world feeling sting of fake drugs. Story

Vaccines News

> Epixis' hep C vaccine show early promise. Piece

> FDA delays decision of Pfizer's Prevnar 13. News

> Inviragen forms dengue partnership with IVI. More

> Start-up Vaxxas lands $16.46M for vaccine nanopatch. Article

> Merck, Serum Institutite sign pneumococcal vaccine deal. Report

And Finally... Scientists are bullish about the potential of a battery-powered skin patch designed to administer a drug for peripheral artery disease, skin ulcers and burns. Release

Suggested Articles

Eli Lilly is combining the oncology team at Lilly Research Laboratories with Loxo Oncology and putting a trio of Loxo execs at the helm.

The failure of SAGE-217 to beat placebo wiped more than 50% off Sage’s share price as investors digested the implications of the data.

The data tee Aurinia up to file for FDA approval next year and go on to address a major unmet medical need.